Case Report: Successful Treatment of Recurrent Urinary Tract Infection Due to Extensively Drug-Resistant Klebsiella Pneumoniae in a Kidney Transplant Recipient Using Chloramphenicol
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
MACHADO, Anna Silva
SILVA, Riberto Garcia da
SOUZA, Ricardo Barbosa Cintra de
COUTINHO, Saurus Mayer
COMELLO, Florencia
PORTO, Ana Paula Matos
LIMA, Daila Sousa
GIOIA, Thais Sabato Romano di
LIMA, Victor Augusto Camarinha Castro
Citação
TRANSPLANTATION PROCEEDINGS, v.55, n.3, p.654-659, 2023
Resumo
Effective therapies for multidrug-resistant (MDR) microorganisms, especially Gram-negative bacteria, are becoming rare. Also, solid-organ transplant recipients are at high risk of MDR Gram-negative bacilli infection. Urinary tract infections are the most frequent bacterial infections in kidney transplant recipients and are an important cause of mortality after renal transplantation. We describe a case of complicated urinary tract infection in a kidney transplant patient due to extensively drug-resistant (XDR) K. pneumoniae treated successfully with a regimen comprising a combination of chloramphenicol and ertapenem. We do not recommend chloramphenicol as a first-line choice for treating complicated urinary tract infections. Still, we believe it is an alterna-tive for infections caused by MDR and/or XDR pathogens in renal transplant patients, as other options are nephrotoxic.
Palavras-chave
Referências
- Aguado JM, 2018, TRANSPLANT REV-ORLAN, V32, P36, DOI 10.1016/j.trre.2017.07.001
- Ah YM, 2014, INT J ANTIMICROB AG, V44, P8, DOI 10.1016/j.ijantimicag.2014.02.016
- Bodro M, 2018, EXPERT REV ANTI-INFE, V16, P723, DOI 10.1080/14787210.2018.1509708
- Brennan-Krohn T, 2017, J ANTIMICROB CHEMOTH, V72, P2775, DOI 10.1093/jac/dkx241
- Cervera C, 2014, CLIN MICROBIOL INFEC, V20, P49, DOI 10.1111/1469-0691.12687
- Civljak R, 2014, EXPERT REV ANTI-INFE, V12, P249, DOI 10.1586/14787210.2014.878647
- Di Bella S, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9070398
- Eliakim-Raz N, 2015, J ANTIMICROB CHEMOTH, V70, P979, DOI 10.1093/jac/dku530
- Freire MP, 2019, EUR J CLIN MICROBIOL, V38, P755, DOI 10.1007/s10096-019-03468-4
- Li ZK, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz368
- Livermore DM, 2011, INT J ANTIMICROB AG, V37, P415, DOI 10.1016/j.ijantimicag.2011.01.012
- MacLaren G, 2017, KUCERS USE ANTIBIOTI, P903
- Noval M, 2020, CURR INFECT DIS REP, V22, DOI 10.1007/s11908-020-0710-9
- Rahim NA, 2015, J ANTIMICROB CHEMOTH, V70, P2589, DOI 10.1093/jac/dkv135
- Tumbarello M, 2018, CURR OPIN INFECT DIS, V31, P566, DOI 10.1097/QCO.0000000000000493
- Wang TZ, 2019, NAT REV NEPHROL, V15, P463, DOI 10.1038/s41581-019-0150-7